ImmunoMet Therapeutics

2:15 PM - 2:30 PM, Monday, February 10, 2020 ・ Ziegfeld
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor with demonstrated impressive in-vivo efficacy in resistant solid tumors. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good safety profile. ImmunoMet has a second program in fibrosis and plans to enter the clinic with IM156 in 2H2020. The company was founded in 2015, is headquartered in the Houston JLABs near MD Anderson, and has raised $19M to date.
Company Type:
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
IM156
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President and CEO
ImmunoMet Therapeutics